Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnesic, and anxiolytic effects

J. Laszlo, R. A. Clark, D. C. Hanson, L. Tyson, L. Crumpler, Richard J. Gralla

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

There currently is no pharmacologic approach to the problem of anticipatory nausea and vomiting (ANV). Lorazepam (Ativan, Wyeth Laboratories, Philadelphia) is an interesting candidate drug if it could block the recall of the unpleasant events associated with chemotherapy, especially if it also has antiemetic properties. Since ANV is a conditioned (learned) response, it may well depend on a memory imprint of the stimulus. This pilot study was designed to use intravenous lorazepam given before and after cisplatin infusion in 32 patients, and to make detailed measurements of nausea, vomiting, recent memory, anxiety, and sedation as well as toxicity. Satisfactory responses occurred in about 70%, as rated separately both by investigator and patient. Forty-six percent did not even recall receiving chemotherapy, regardless of whether or not they vomited; 80% had no significant anxiety about chemotherapy. Adverse reactions included some cases of perceptual disturbance, urinary incontinence, diarrhea, hypotension, and one case of severe transient amnesia. No long-term adverse effects were noted.

Original languageEnglish (US)
Pages (from-to)864-869
Number of pages6
JournalJournal of Clinical Oncology
Volume3
Issue number6
StatePublished - 1985
Externally publishedYes

Fingerprint

Lorazepam
Antiemetics
Anticipatory Vomiting
Anti-Anxiety Agents
Nausea
Cisplatin
Drug Therapy
Anxiety
Pharmaceutical Preparations
Neoplasms
Amnesia
Urinary Incontinence
Hypotension
Vomiting
Diarrhea
Research Personnel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Laszlo, J., Clark, R. A., Hanson, D. C., Tyson, L., Crumpler, L., & Gralla, R. J. (1985). Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnesic, and anxiolytic effects. Journal of Clinical Oncology, 3(6), 864-869.

Lorazepam in cancer patients treated with cisplatin : A drug having antiemetic, amnesic, and anxiolytic effects. / Laszlo, J.; Clark, R. A.; Hanson, D. C.; Tyson, L.; Crumpler, L.; Gralla, Richard J.

In: Journal of Clinical Oncology, Vol. 3, No. 6, 1985, p. 864-869.

Research output: Contribution to journalArticle

Laszlo, J, Clark, RA, Hanson, DC, Tyson, L, Crumpler, L & Gralla, RJ 1985, 'Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnesic, and anxiolytic effects', Journal of Clinical Oncology, vol. 3, no. 6, pp. 864-869.
Laszlo, J. ; Clark, R. A. ; Hanson, D. C. ; Tyson, L. ; Crumpler, L. ; Gralla, Richard J. / Lorazepam in cancer patients treated with cisplatin : A drug having antiemetic, amnesic, and anxiolytic effects. In: Journal of Clinical Oncology. 1985 ; Vol. 3, No. 6. pp. 864-869.
@article{fb7c0bafd19f47109d44d6c7743745d7,
title = "Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnesic, and anxiolytic effects",
abstract = "There currently is no pharmacologic approach to the problem of anticipatory nausea and vomiting (ANV). Lorazepam (Ativan, Wyeth Laboratories, Philadelphia) is an interesting candidate drug if it could block the recall of the unpleasant events associated with chemotherapy, especially if it also has antiemetic properties. Since ANV is a conditioned (learned) response, it may well depend on a memory imprint of the stimulus. This pilot study was designed to use intravenous lorazepam given before and after cisplatin infusion in 32 patients, and to make detailed measurements of nausea, vomiting, recent memory, anxiety, and sedation as well as toxicity. Satisfactory responses occurred in about 70{\%}, as rated separately both by investigator and patient. Forty-six percent did not even recall receiving chemotherapy, regardless of whether or not they vomited; 80{\%} had no significant anxiety about chemotherapy. Adverse reactions included some cases of perceptual disturbance, urinary incontinence, diarrhea, hypotension, and one case of severe transient amnesia. No long-term adverse effects were noted.",
author = "J. Laszlo and Clark, {R. A.} and Hanson, {D. C.} and L. Tyson and L. Crumpler and Gralla, {Richard J.}",
year = "1985",
language = "English (US)",
volume = "3",
pages = "864--869",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Lorazepam in cancer patients treated with cisplatin

T2 - A drug having antiemetic, amnesic, and anxiolytic effects

AU - Laszlo, J.

AU - Clark, R. A.

AU - Hanson, D. C.

AU - Tyson, L.

AU - Crumpler, L.

AU - Gralla, Richard J.

PY - 1985

Y1 - 1985

N2 - There currently is no pharmacologic approach to the problem of anticipatory nausea and vomiting (ANV). Lorazepam (Ativan, Wyeth Laboratories, Philadelphia) is an interesting candidate drug if it could block the recall of the unpleasant events associated with chemotherapy, especially if it also has antiemetic properties. Since ANV is a conditioned (learned) response, it may well depend on a memory imprint of the stimulus. This pilot study was designed to use intravenous lorazepam given before and after cisplatin infusion in 32 patients, and to make detailed measurements of nausea, vomiting, recent memory, anxiety, and sedation as well as toxicity. Satisfactory responses occurred in about 70%, as rated separately both by investigator and patient. Forty-six percent did not even recall receiving chemotherapy, regardless of whether or not they vomited; 80% had no significant anxiety about chemotherapy. Adverse reactions included some cases of perceptual disturbance, urinary incontinence, diarrhea, hypotension, and one case of severe transient amnesia. No long-term adverse effects were noted.

AB - There currently is no pharmacologic approach to the problem of anticipatory nausea and vomiting (ANV). Lorazepam (Ativan, Wyeth Laboratories, Philadelphia) is an interesting candidate drug if it could block the recall of the unpleasant events associated with chemotherapy, especially if it also has antiemetic properties. Since ANV is a conditioned (learned) response, it may well depend on a memory imprint of the stimulus. This pilot study was designed to use intravenous lorazepam given before and after cisplatin infusion in 32 patients, and to make detailed measurements of nausea, vomiting, recent memory, anxiety, and sedation as well as toxicity. Satisfactory responses occurred in about 70%, as rated separately both by investigator and patient. Forty-six percent did not even recall receiving chemotherapy, regardless of whether or not they vomited; 80% had no significant anxiety about chemotherapy. Adverse reactions included some cases of perceptual disturbance, urinary incontinence, diarrhea, hypotension, and one case of severe transient amnesia. No long-term adverse effects were noted.

UR - http://www.scopus.com/inward/record.url?scp=0021879894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021879894&partnerID=8YFLogxK

M3 - Article

C2 - 4040158

AN - SCOPUS:0021879894

VL - 3

SP - 864

EP - 869

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -